Related Experiment Video

Updated: May 10, 2026

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
11:31

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

Anti-CD3 clinical trials in type 1 diabetes mellitus

Anastasia G Daifotis1, Scott Koenig, Lucienne Chatenoud

  • 1MacroGenics, Inc. 9640 Medical Center Drive, Rockville, MD 20850, USA.

Clinical Immunology (Orlando, Fla.)
|June 4, 2013
PubMed

Insights

Humanized anti-CD3 monoclonal antibodies (mAbs) like teplizumab show promise for type 1 diabetes (T1D) treatment. Adequate dosing improved C-peptide responses and reduced insulin needs for up to two years.

Area of Science:

  • Immunology
  • Endocrinology
  • Pharmacology

Background:

  • Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction of insulin-producing beta cells.
  • Current T1D management focuses on insulin replacement therapy, which does not address the underlying autoimmune process.
  • Humanized anti-CD3 monoclonal antibodies (mAbs) have emerged as a potential immunomodulatory therapy for T1D.

Purpose of the Study:

  • To evaluate the efficacy and safety of humanized anti-CD3 mAbs (teplizumab, otelixizumab) in new-onset T1D patients.
  • To assess the impact of different dosing regimens on clinical outcomes.
  • To explore potential mechanisms of action and identify patient subgroups that benefit most.

Main Methods:

  • Clinical trials involving over 1500 subjects aged 7-45 with new or recent-onset T1D.
  • Administration of varying intravenous doses (3-48mg) and regimens (6-14 days, single or repeat courses) of anti-CD3 mAbs.
  • Assessment of stimulated C-peptide responses, exogenous insulin requirements, T cell counts, and adverse events.

Main Results:

  • Adequate dosing of anti-CD3 mAbs led to improved stimulated C-peptide responses and reduced insulin needs for at least two years post-diagnosis.
  • Treatment resulted in transient reductions in circulating T cells, suggesting a potential mechanism involving regulatory immune induction.
  • Infusion-related adverse effects were transient and manageable.
  • Significant differences in efficacy were observed across patient groups.

Conclusions:

  • Humanized anti-CD3 mAbs demonstrate clinical efficacy in preserving beta cell function and reducing insulin dependence in new-onset T1D.
  • The mechanism of action likely involves immune modulation and induction of regulatory pathways.
  • Personalizing immunotherapy by identifying specific patient characteristics is crucial for optimizing treatment outcomes in T1D.
Keywords:
Anti-CD3OtelixizumabTeplizumabType 1 diabetes mellitus

More Related Videos

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells06:27

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Related Concept Videos

Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...